 |
|
Results of Total Pancreatectomy for Adenocarcinoma of the Pancreas
Howard M. Karpoff, MD;
David S. Klimstra, MD;
Murray F. Brennan, MD;
Kevin C. Conlon, MD, MBA
Arch Surg. 2001;136:44-47.
Hypothesis Total pancreatectomy for infiltrating ductal adenocarcinoma is not superior to pancreaticoduodenectomy or distal pancreatectomy.
Design A retrospective analysis of a prospective database of patients.
Setting Memorial Sloan-Kettering Cancer Center, New York, NY.
Patients All patients (n = 488) undergoing pancreatic resection.
Main Outcome Measures Duration of operation, estimated blood loss, complications, length of stay, number of positive lymph nodes, presence of a positive margin, and survival times were analyzed.
Results Thirty-five patients were identified who underwent total pancreatectomy, 28 of whom had adenocarcinoma. Median length of stay was 32 days; 19 (54%) developed postoperative complications, of which 63% were infectious. Thirty-day mortality was 3% (1 patient). Median survival was 9.3 months (range, 0.6-172 months). There was no significant difference between patients with and without adenocarcinoma in terms of duration of operation, estimated blood loss, complications, length of stay, or number of readmissions. In patients with adenocarcinoma, margin or nodal status were not significant survival variables. Patients undergoing total pancreatectomy for adenocarcinoma had a significantly worse overall survival than those undergoing total pancreatectomy for other reasons (P<.001), or compared with a contemporaneous cohort with adenocarcinoma undergoing pancreaticoduodenectomy (n = 409) and distal pancreatectomy (n = 51) (7.9 vs 17.2 months; P<.002).
Conclusions Total pancreatectomy can be performed safely with low mortality; survival is predicted by the underlying pathologic findings: patients undergoing total pancreatectomy for adenocarcinoma have a uniformly poor outcome. Those undergoing total pancreatectomy for benign disease or nonadenocarcinoma variants can have long-term survival. In patients who require total pancreatectomy for ductal adenocarcinoma, the survival is so poor as to bring into question the value of the operation.
From the Departments of Surgery (Drs Karpoff, Brennan, and Conlon) and Pathology (Dr Klimstra), Memorial Sloan-Kettering Cancer Center, New York, NY.
RELATED ARTICLES
Archives of Surgery Reader's Choice: Continuing Medical Education
Arch Surg. 2001;136(1):120-121.
FULL TEXT
Results of Total Pancreatectomy for Adenocarcinoma of the Pancreas—Invited Critique
A. R. Moossa
Arch Surg. 2001;136(1):48.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Variations in Surgical Treatment and Outcomes of Patients With Pancreatic Cancer: A Population-Based Study
Govindarajan et al.
Ann. Surg. Oncol. 2008;15:175-185.
ABSTRACT
| FULL TEXT
Extended Resection for Pancreatic Adenocarcinoma
Reddy et al.
The Oncologist 2007;12:654-663.
ABSTRACT
| FULL TEXT
An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.
Greenhalf
Gut 2006;55:1533-1535.
FULL TEXT
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins
Kim et al.
Gut 2006;55:1598-1605.
ABSTRACT
| FULL TEXT
Is Reporting of Recurrence Data Important in Pancreatic Cancer?
Meyers et al.
Ann. Surg. Oncol. 2004;11:304-309.
ABSTRACT
| FULL TEXT
|
